VIVUS Inc. (VVUS)

3.30
NASDAQ : Health Technology
Prev Close 3.27
Day Low/High 3.23 / 3.36
52 Wk Low/High 2.15 / 9.10
Avg Volume 47.50K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 34.78M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Pending Sarepta Results, Cyclacel

Biotech Stock Mailbag: Pending Sarepta Results, Cyclacel

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Weight Loss Pills Not a Threat, Says Medifast CEO

Weight Loss Pills Not a Threat, Says Medifast CEO

Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.

Higher Prices Favored

This market should have broken during the summer, but it didn't and there are now multiple tailwinds.

Cramer's 'Mad Money' Recap: No Day of Reckoning

Cramer's 'Mad Money' Recap: No Day of Reckoning

The market's problems are more like a laundry list of things that must be done rather than a great unknown waiting to destroy us all, Cramer said

Vivus Beats Arena Pharma With Obesity Drug Launch

Vivus Beats Arena Pharma With Obesity Drug Launch

Vivus' Qsymia still faces questions about pricing compared to generics.

The Next Big Thing in Biotech: Obesity Drugs

The Next Big Thing in Biotech: Obesity Drugs

Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.

The Essential 2012 Biotech Stock Fall Preview

The Essential 2012 Biotech Stock Fall Preview

If you're a biotech investor not following these stocks this fall, you're not paying attention.

2012 Biotech Stock Predictions: An Interim Report Card

2012 Biotech Stock Predictions: An Interim Report Card

Check out the accuracy of the 2012 biotech sector predictions made by Adam Feuerstein

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

The Next Big Thing in Biotech: FDA Approvals

The Next Big Thing in Biotech: FDA Approvals

Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.

Six Must-Follow Earnings for Aug. 7

Six Must-Follow Earnings for Aug. 7

Sirius XM Radio and Walt Disney are among the widely followed companies that report earnings on Tuesday.

<I>TheStreet</I> Readers Make Perfect Predictions in Drug-Approval Contest

TheStreet Readers Make Perfect Predictions in Drug-Approval Contest

Eleven contestants correctly predicted all five FDA events.

Amarin Insiders Rush to Sell Stock One Day After Fish-Oil Pill Approval

Amarin Insiders Rush to Sell Stock One Day After Fish-Oil Pill Approval

The timing of Amarin's insider sales are unsettling given the questions that linger over Vascepa's future.

Biotech Stock Mailbag: Amarin, Sarepta

Biotech Stock Mailbag: Amarin, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon will sell Rayos as a morning pain relief for patients with rheumatoid arthritis.

Top 5 Must-Follow Earnings for Monday

Top 5 Must-Follow Earnings for Monday

Monday promises a full day of surprises and disappointments. These are the most likely to move the market.

Amarin: Prepping for FDA Approval Decision

Amarin: Prepping for FDA Approval Decision

A primer on all you need to know as Amarin waits on FDA's decision to approve its prescription fish oil pill.

Biotech Stock Mailbag: Peregrine Pharma

Biotech Stock Mailbag: Peregrine Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

4 Biotech Stocks Surging on Huge Volume

4 Biotech Stocks Surging on Huge Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Analysts' Actions: CAT, HOT, VVUS, AMGN

Analysts' Actions: CAT, HOT, VVUS, AMGN

Here are today's top research calls.

Media Embargo Secrets Exposed: How and Why Companies Share Stock-Moving News

Media Embargo Secrets Exposed: How and Why Companies Share Stock-Moving News

An insider's look at the practice of media embargoes and why they can lead to disaster.

Vivus Weight-Loss Pill Approved -- Maybe?

Vivus Weight-Loss Pill Approved -- Maybe?

Vivus' Qnexa is the second weight-loss pill approved by FDA in the past three weeks.

The Next Big Thing in Biotech: Vivus

The Next Big Thing in Biotech: Vivus

Adam Feuerstein, senior columnist for TheStreet, says Vivus is the next big thing in biotech.

Cramer's 'Mad Money' Recap: Pay Attention and Prosper

Cramer's 'Mad Money' Recap: Pay Attention and Prosper

Dozens of companies will report earnings soon and they will forecast the fates of countless others, Cramer said.

Arena Pharma's Weight-Loss Pill Has Few Fans in Japan

Arena Pharma's Weight-Loss Pill Has Few Fans in Japan

The Japanese sell-side community doesn't see Belviq as a blockbuster weight-loss pill.

Vivus Insiders Sell Stock Ahead of Crucial FDA Approval Decision

Vivus Insiders Sell Stock Ahead of Crucial FDA Approval Decision

FDA expected to make approval decision on Vivus' weight-loss pill Qnexa on July 17.

TheStreet Quant Rating: D (Sell)